Table 3.
Univariate analysis of clinical parameters and potential markers with regard to PFS and OS
| Variables | Number | Median PFS (months) | P | Median OS (months) | P |
|---|---|---|---|---|---|
| Gender | |||||
| Male | 46 | 16.2 | 0.015 | 39.2 | 0.033 |
| Female | 13 | 12.0 | 26.2 | ||
| Age (years) | |||||
| ≤60 | 39 | 13.8 | 0.961 | 37.6 | 0.261 |
| >60 | 20 | 13.7 | 46.8 | ||
| Pathological grade | |||||
| G1 | 12 | 21.3 | 0.135 | 42.0 | 0.636 |
| G2 | 24 | 13.8 | 38.6 | ||
| G3 | 23 | 12.6 | 37.6 | ||
| Number of disease sites | |||||
| 2 or less | 48 | 16.6 | 0.010 | 39.9 | 0.008 |
| >2 | 11 | 9.7 | 21.7 | ||
| Hypertension | |||||
| No | 19 | 9.5 | 0.095 | 38.4 | 0.055 |
| Yes | 40 | 16.2 | 39.9 | ||
| Hand-foot skin reaction | |||||
| No | 19 | 13.7 | 0.861 | 39.2 | 0.812 |
| Yes | 40 | 14.0 | 38.6 | ||
| Hypothyroidism | |||||
| No | 32 | 13.8 | 0.702 | 39.9 | 0.229 |
| Yes | 27 | 14.0 | 34.0 | ||
| Hyperlipidemia | |||||
| No | 18 | 13.1 | 0.650 | 38.6 | 0.456 |
| Yes | 41 | 16.2 | 37.6 | ||
| Fatigue | |||||
| No | 26 | 13.7 | 0.580 | 38.6 | 0.793 |
| Yes | 33 | 13.8 | 37.6 | ||
| VHL gene | |||||
| Wild-type | 48 | 13.8 | 0.257 | 39.2 | 0.873 |
| Mutation | 11 | 21.3 | 34.6 | ||
| VEGFR-1 | |||||
| Negative | 19 | 12.1 | 0.056 | 38.4 | 0.052 |
| Positive | 40 | 16.2 | 39.2 | ||
| VEGFR-2 | |||||
| Negative | 17 | 12.9 | 0.026 | 46.8 | 0.626 |
| Positive | 42 | 17.6 | 38.6 | ||
| VEGFR-3 | |||||
| Negative | 38 | 13.8 | 0.586 | 38.6 | 0.259 |
| Positive | 21 | 17.6 | 37.6 | ||
| KIT | |||||
| Negative | 38 | 12.6 | 0.043 | 38.6 | 0.382 |
| Positive | 21 | 22.2 | 38.4 | ||
| Therapy | |||||
| Sunitinib | 48 | 13.8 | 0.912 | 38.4 | 0.534 |
| Pazopanib | 11 | 16.6 | 45.8 |
VEGFR: Vascular endothelial growth factor receptors; VHL: Von Hippel-Lindau; PFS: Progression-free survival; OS: Overall survival.